Pan-cancer approval shows huge potential for antibody–drug conjugates

Enhertu (trastuzumab deruxtecan), has become the first antibody–drug conjugate (ADC) to receive US approval for treating cancer based on the molecular profile of the tumour rather than its location of origin. The approval is based on positive results from clinical trials of the drug against a range of cancers expressing human epidermal growth factor receptor 2 (HER2).